HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum

Chen, Zhuming; Ali, Muhammad; Kai, Zhe; Wang, Yan; Ali, Muhammad

doi:10.1007/s12094-022-03004-5

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a significant survival advantage after 3 years in patients that underwent CRS and HIPEC (RR = 0.63, 95% CI 0.36–1.07, p < 0.05). However, there was no significant difference in the 1-year and 5-year overall survival [ 20 ]. Consistent with these results, Desiderio et al reported no survival advantage in patients with gastric cancer and proven peritoneal metastasis treated with neoadjuvant systemic chemotherapy and gastrectomy plus HIPEC in comparison to patients that underwent neoadjuvant chemotherapy and gastrectomy without HIPEC.…”

Section: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemo...mentioning

confidence: 99%

Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations

Acs,

Piso,

Glockzin

2024

Current Oncology

View full text Add to dashboard Cite

Peritoneal metastasis is a common finding in patients with advanced gastric cancer. Beyond systemic chemotherapy, additive local treatments such as cytoreductive surgery and intraperitoneal chemotherapy are considered an inherent part of different multimodal treatment concepts for selected patients with peritoneal metastatic gastric cancer. This review article discusses the role of cytoreductive surgery (CRS) and intraperitoneal chemotherapy, including HIPEC, NIPS, and PIPAC, as additive therapeutic options with curative and palliative intent.

show abstract

Section: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemo...mentioning

confidence: 99%

Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations

Acs,

Piso,

Glockzin

2024

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Peritoneal carcinomatosis occurs in 20–30% of patients during the natural course of disease and is considered the most common non-curable factor in stage IV GC [ 4 , 5 , 6 , 7 ]. Apart from a dismal prognosis, PM contributes to a significant quality of life (QoL) deterioration due to numerous comorbidities, including ascites, intestinal obstruction, chronic pain, malnutrition and cachexia [ 8 ]. According to the National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) recommendations, management of metastatic disease should involve systemic therapy and best supportive care [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Oncological Outcomes and Long-Term Survival among Patients with Gastric Cancer and Limited Peritoneal Disease Progression after Neoadjuvant Chemotherapy

Kobiałka,

Sędłak,

Pelc

et al. 2023

JCM

View full text Add to dashboard Cite

Introduction: The role of surgery in stage IV gastric cancer with peritoneal metastasis (PM) remains unclear. The objective of the current single-center study was to define the impact of gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on outcomes among Central European GC patients with limited peritoneal disease progression after neoadjuvant chemotherapy (NAC). Methods: Patients with histologically confirmed GC who underwent curative-intent multimodal treatment between 2013 and 2023 were included. Patients without adenocarcinoma, who did not undergo gastrectomy, had early (cT1) or metastatic GC at the time of initial diagnosis, who underwent multivisceral resection, incomplete cytoreduction or palliative care, died before planned curative-intent treatment, or had incomplete clinical or pathological missing information were excluded. Results: A total of 74 patients who underwent curative-intent treatment for GC with PM were included in the final analytic cohort. Patients who underwent gastrectomy with CRS+HIPEC were less likely to achieve TOO (CRS+HIPEC: 28% vs. CRS: 57.1%, p = 0.033) compared with individuals after CRS alone. Specifically, patients who underwent gastrectomy with CRS+HIPEC had a higher likelihood of postoperative complications (CRS+HIPEC: 48% vs. CRS: 20.4%, p = 0.018) and longer hospital LOS (median, CRS+HIPEC: 12 vs. CRS: 10, p = 0.019). While administration of HIPEC did not impact long-term survival (median OS, CRS+HIPEC: 16 months vs. CRS: 12 months, p = 0.55), postoperative complications (median OS, CCI < 30:16 months vs. CCI > 30:5 months, p = 0.024) and ICU stay (median OS, no ICU stay: 16 months vs. ICU stay: 5 months, p = 0.008) were associated with worsened long-term survival among GC patients with PM. Conclusions: Data from the current study demonstrated a lack of survival benefit among advanced GC patients with PM undergoing gastrectomy with CRS+HIPEC when compared with individuals after gastrectomy with CRS alone. Administration of perioperative chemotherapy and achievement of TO failed to withstand the peritoneal disease progression during NAC.

show abstract

HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum

Cited by 2 publications

References 17 publications

Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations

Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations

Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Oncological Outcomes and Long-Term Survival among Patients with Gastric Cancer and Limited Peritoneal Disease Progression after Neoadjuvant Chemotherapy

Contact Info

Product

Resources

About